NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
Am-Pharma announces publication of in vivo acute kidney injury study demonstrating ilofotase alfa’s dual protective mechanism<
05 Jul 2022

Am-Pharma announces publication of in vivo acute kidney injury study demonstrating ilofotase alfa’s dual protective mechanism

Study shows ilofotase alfa protects against ischemia-reperfusion induced acute kidney injury in rodents
Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer<
30 Jun 2022

Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Aura expects to initiate the trial in the second half of 2022, with initial Phase 1 data expected in 2023.
Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma<
22 Jun 2022

Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma

In this Retrospective Matched Case Control Study, Belzupacap Sarotalocan Achieved Statistically Significant Vision Preservation
Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting<
17 Jun 2022

Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting

We remain on track with our Phase 2 SC study and we plan to finalize a decision on the route of administration and initiate our pivotal program before the end of the year.
LAVA Therapeutics highlights encouraging clinical updates on lead program, LAVA-051, in chronic lymphocytic leukemia and multiple myeloma patients<
16 Jun 2022

LAVA Therapeutics highlights encouraging clinical updates on lead program, LAVA-051, in chronic lymphocytic leukemia and multiple myeloma patients

James Noble and Jay Backstrom, M.D, M.P.H, bring vast global leadership experiences at public biopharmaceutical companies
Ysios Capital appoints Wen Wen Cheng as Head of Legal<
16 Jun 2022

Ysios Capital appoints Wen Wen Cheng as Head of Legal

This addition will strengthen the Ysios Capital team by incorporating an expert in legal matters.
LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients<
16 Jun 2022

LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients

James Noble and Jay Backstrom, M.D, M.P.H, bring vast global leadership experiences at public biopharmaceutical companies
Galecto Announces First Patient Enrolled in Phase 2 Trial of GB1211 in Combination with Atezolizumab for First-Line Treatment of NSCLC<
16 Jun 2022

Galecto Announces First Patient Enrolled in Phase 2 Trial of GB1211 in Combination with Atezolizumab for First-Line Treatment of NSCLC

GB1211, Galecto’s galectin-3 inhibitor, has shown potent anti-tumor effects and increased efficacy of checkpoint inhibition in pre-clinical models
LAVA Therapeutics Announces Two Appointments to its Board of Directors<
15 Jun 2022

LAVA Therapeutics Announces Two Appointments to its Board of Directors

James Noble and Jay Backstrom, M.D, M.P.H, bring vast global leadership experiences at public biopharmaceutical companies
Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension<
09 Jun 2022

Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension

Ysios Capital has joined an international investor syndicate led by RA Capital Management and Andera Partners.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка